EGFR and non-small cell lung carcinoma: In these studies, the 2-year disease-free survival of the patients with stage II to IIIA EGFR-mutated NSCLC in the osimertinib group was 90% [4], and the 2-year disease-free survival of the patients with stage II to IIIA NSCLC in the atezolizumab group was 71.4% [6].